Drug Eluting Embolization Particles
- User: Female
- Hormonal: Non-Hormonal
-
Delivery type:
- Fallopian Tube
-
Intended Duration:
- Permanent
- Development Stage: Pre-Clinical
- Developer(s)/researcher(s): University of Washington, Oregon Health & Science University
Details
- API: To Be Finalized - Tested with Doxycycline and Phenyl Benzoate
-
Mechanism of Action:
- Tubal Occlusion
- Inactive Materials: PLGA, PCL
- Regimen: Permanent
- MPT: Not Potential MPT
- Promising Attributes: The method would provide users with a non-surgical alternative for permanent contraception.
Product Status
Active/Recent Pre-Clinical Development
History
2014: OHSU launches the Oregon Permanent Contraceptive Research Center (OPERM), with support from the Gates Foundation, intended to identify nonsurgical permanent contraceptive methods.
2018: Objective of OPERM transitions to completing IND-enabling pre-clinical development of one or more approaches to nonsurgical permanent contraception to be able to enter clinical trials. While transcervical polidocanol foam has emerged as their primary candidate product, development has continued for other concepts.
2022: OHSU and the University of Washington publish analysis of the potential for drug loaded electrospun fiber microparticles to produce a consistent inflammatory effect in the fallopian tubes.